White House strikes new deals to lower prices on obesity drugs for some

By Sydney Lupkin

Published November 7, 2025 at 4:56 AM EST

The Trump administration struck deals with pharmaceutical companies Novo Nordisk and Eli Lilly to lower prices and copays for type 2 diabetes and obesity drugs --- but not everyone will qualify.

Sydney Lupkin

Sydney Lupkin is the pharmaceuticals correspondent for NPR.

See stories by Sydney Lupkin

Together we’ve already reduced WKAR’s $1.6 million budget gap created by the loss of federal funding. With your sustaining support we can close the remaining $500,000 gap and keep trusted public media strong for mid-Michigan. The best way to support WKAR is to become a sustainer. Already a sustainer? Please consider upgrading your current monthly gift.

DONATE to close the gap